Previous 10 | Next 10 |
2024-05-29 07:31:31 ET SRDX stock price gained 18.4% More on Surmodics Surmodics, Inc. (SRDX) Q2 2024 Earnings Call Transcript Surmodics beats top-line and bottom-line estimates; updates FY24 outlook Needham sees BSX, CNMD, RMD beating Street, despite medtech...
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise acro...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 2.3% to $12.22 on volume of 208,602,591 shares CytomX Therapeutics Inc. (CTMX) rose 214.7% to $5.13 on volume of 203,288,355 shares Akanda Corp. (AKAN) rose 25.4% to $0.1166 on volume of 179,349,234 shares ...
2024-05-01 16:07:10 ET Surmodics, Inc. (SRDX) Q2 2024 Earnings Conference Call May 1, 2024 08:00 ET Company Participants Gary Maharaj - President and Chief Executive Officer Timothy Arens - Chief Financial Officer Conference Call Participants Brooks O...
Surmodics, Inc. (NASDAQ: SRDX) is one of today's top gainers. The company's shares have moved 29.01% on the day to $33.14. Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnos...
A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 52.9% to $0.1422 on volume of 108,274,564 shares CytomX Therapeutics Inc. (CTMX) rose 71.8% to $2.8 on volume of 31,588,176 shares Getaround Inc. (GETR) rose 35.9% to $0.2754 on volume of 26,693,135 shares P...
Announces Commercial Launch of Two New Thrombectomy Devices for the Venous and Arterial Vasculatures: Pounce™ Venous and Pounce LP (Low Profile) Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, t...
Earnings Conference Call and Webcast Will Begin at 7:00 am (CT) Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be release...
2024-04-19 04:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-14 17:56:08 ET More on Boston Scientific, CONMED, etc. ResMed: Not A Sleeper Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash Boston Scientific: The Market's Newest Mega-Cap Needs A Breather Mizuho sees ResMed as 'overwhelming ben...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Surmodics, Inc. (NASDAQ:SRDX)'s sale ...
Access to Premier’s healthcare group purchasing organization (GPO) expected to expand national market reach for Surmodics endovascular thrombectomy solutions. Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announce...
NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Stericycle, Inc. (NASDAQ:SRCL)'s sale...